Contact
searchSearch
HMP Global

Drug Recalls Topic Center

The Latest

News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Subpotent Thyroid USP Bulk Drug Distributed Nationwide
01/22/2026
Grace Taylor, MS, MA
A voluntary Class II recall is underway for a bulk thyroid USP drug product after testing showed it was subpotent, raising concerns for manufacturers and pharmacists relying on accurate thyroid hormone strength.
A voluntary Class II recall is underway for a bulk thyroid USP drug product after testing showed it was subpotent, raising concerns for manufacturers and pharmacists relying on accurate thyroid hormone strength.
A voluntary Class II recall is...
01/22/2026
Pharmacy Learning Network
News
Furosemide 40 mg Tablets Recalled Due to Foreign Substance Contamination
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
SpecGx Initiates Class II Recall of Oxycodone/Acetaminophen Tablets Over Missing Imprint Risk
01/15/2026
Juliet Gallagher
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
BD ChloraPrep Triple Swabsticks Recalled Due to Sterility Concerns
01/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug...
01/07/2026
Pharmacy Learning Network
News
Class II Recall for Ondansetron Orally Disintegrating Tablets Due to Packaging Defect
01/07/2026
Hannah Musick
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for...
01/07/2026
Pharmacy Learning Network

Newsfeed

News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Furosemide 40 mg Tablets Recalled Due to Foreign Substance Contamination
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
SpecGx Initiates Class II Recall of Oxycodone/Acetaminophen Tablets Over Missing Imprint Risk
01/15/2026
Juliet Gallagher
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
BD ChloraPrep Triple Swabsticks Recalled Due to Sterility Concerns
01/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug...
01/07/2026
Pharmacy Learning Network
News
Class II Recall for Ondansetron Orally Disintegrating Tablets Due to Packaging Defect
01/07/2026
Hannah Musick
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for...
01/07/2026
Pharmacy Learning Network
PharmLaw
Iowa Attorney General Accuses Insulin Makers and PBMs of Deceptive Pricing Practices
02/03/2026
Juliet Gallagher
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna...
02/03/2026
Pharmacy Learning Network
News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
PharmLaw
PCMA Sues California Over SB 41, Challenging PBM Fiduciary Duties Under ERISA
01/27/2026
Juliet Gallagher
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious...
01/27/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Furosemide 40 mg Tablets Recalled Due to Foreign Substance Contamination
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
PharmLaw
Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged GLP-1 Antitrust Violations
01/21/2026
Juliet Gallagher
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding...
01/21/2026
Pharmacy Learning Network
News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use